Allergan's Restasis patent invalidated — 4 key notes

A federal judge in Texas invalidated Allergan's patent for Restasis, its dry eye medicine drug, saying the patent covered "obvious ideas," CNBC reports.

Here's what you should know:

1. Judge William Bryson issued the ruling, which will allow generic drugmakers to sell their own versions of Restasis.

2. Allergan was under scrutiny over its decision to transfer Restasis' patent rights to a Native American tribe. Allergan made the move to protect the drug from administrative review. Allergan said it would not invoke the tribe's sovereign immunity in court, however.
https://www.beckersasc.com/gastroenterology-and-endoscopy/allergan-under-scrutiny-for-patent-dodging-4-insights.html

3. Restasis accounted for $1.5 billion in Allergan's sales in 2016. It was more than 10 percent of the company's revenue.

4. Allergan's stock tumbled from $205.08 to $192.85 following the news of the judge's ruling Oct. 16. As of noon Oct. 17, the stock was back trading at $200.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast